Dynamic Analysis of Circulating Tumor DNA to Predict the

Prognosis and Monitor the Treatment Response of Patients

with Metastatic Triple-negative Breast Cancer: a prospective

4 study

- 6 Yajing Chi^{1,2}, Mu Su³, Dongdong Zhou¹, Fangchao Zheng¹, Baoxuan Zhang¹, Ling
- 7 Qiang¹, Guohua Ren¹, Lihua Song¹, Bing Bu¹, Shu Fang¹, Bo Yu³, Jinxing Zhou³,
- 8 Jinming Yu^{4#}, Huihui Li^{1#}

1

2

3

5

- 9 1. Department of Breast Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical
- 10 University and Shandong Academy of Medical Sciences, Jinan, Shandong Province, China.
- 2. School of Medicine, Nankai University, Tianjin, China
- 12 3. Department of Bioinformatics, Berry Oncology Corporation, Beijing, China.
- 13 4. Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University
- and Shandong Academy of Medical Sciences, Jinan, Shandong Province, China.
- 15 *Corresponding author:
- 16 Huihui Li, Department of Breast Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First
- 17 Medical University and Shandong Academy of Medical Sciences, No.440, Jiyan Road, Huaiyin District, Jinan,
- 18 Shandong Province, China, Zip: 250017, Tel: +86 15553103209, Email: huihuili82@163.com.
- 19 Jinming Yu, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical
- 20 University and Shandong Academy of Medical Sciences, Jinan, 250017, Shandong Province, China. Email:
- 21 <u>sdyujinming@163.com</u>.

Abstract

- 23 **Background**: Limited data are available on the application of circulating tumor DNA
- 24 (ctDNA) in metastatic triple-negative breast cancer (mTNBC) patients. Here, we
- 25 investigated the value of ctDNA for predicting the prognosis and monitoring the
- 26 treatment response in mTNBC patients.
- 27 Methods: We prospectively enrolled 70 Chinese patients with mTNBC who had
- progressed after ≤ 2 lines of chemotherapy and collected blood samples to extract
- 29 ctDNA for 457-gene targeted panel sequencing.
- 30 **Results:** Patients with ctDNA+, defined by 12 prognosis-relevant mutated genes, had
- a shorter progression-free survival (PFS) than ctDNA- patients (5.16 months vs. 9.05
- months, P = 0.001) and ctDNA+ was independently associated with a shorter PFS (HR,
- 95%CI: 2.67, 1.2–5.96; P = 0.016) by multivariable analyses. Patients with a higher
- 34 NOTERTHER pleasifiche din mour checken organises the (label AETHI) especially level who should have a tall phose at a label a firmation inc.

- (ctDNA% \geq 0.05) had a significantly shorter PFS than patients with a lower MATH
- score (5.67 months vs. 11.27 months, P = 0.007) and patients with a lower ctDNA%
- 37 (5.45 months vs. 12.17 months, P < 0.001), respectively. Positive correlations with
- treatment response were observed for MATH score (R = 0.24, P = 0.014) and ctDNA%
- 39 (R = 0.3, P = 0.002), but not the CEA, CA125, or CA153. Moreover, patients who
- 40 remained ctDNA+ during dynamic monitoring tended to have a shorter PFS than those
- 41 who did not (3.90 months *vs.* 6.10 months, P = 0.135).
- 42 Conclusions: ctDNA profiling provides insight into the mutational landscape of
- 43 mTNBC and may reliably predict the prognosis and treatment response of mTNBC
- 44 patients.

54

- 45 **Funding:** This work was supported by the National Natural Science Foundation of
- 46 China (Grant No. 81902713), Natural Science Foundation of Shandong Province (Grant
- No. ZR2019LZL018), Breast Disease Research Fund of Shandong Provincial Medical
- 48 Association (Grant No. YXH2020ZX066), the Start-up Fund of Shandong Cancer
- 49 Hospital (Grant No. 2020-PYB10), Beijing Science and Technology Innovation Fund
- 50 (Grant No. KC2021-ZZ-0010-1).
- 51 **Keywords:** Circulating tumor DNA; metastatic triple-negative breast cancer; next-
- 52 generation sequencing; prognosis; treatment response

Introduction

- Breast cancer is the most common malignant tumor and the leading cause of cancer-
- related deaths in women worldwide(Sung et al., 2021). Triple-negative breast cancer
- 57 (TNBC) represents 15%–20% of all breast cancer cases and exhibits a more aggressive
- 58 phenotype (with a poorer prognosis) than non-TNBC(Foulkes, Smith, & Reis-Filho,
- 59 2010; X. Li et al., 2017; Malorni et al., 2012). Due to the absence of human epidermal
- growth factor receptor 2 (HER2), estrogen receptor (ER), or progesterone receptor (PR)
- expression, TNBC lacks effective targeted therapies and treatment regimens. Patients
- with mTNBC have fewer available treatment options and exhibit worse survival than
- early-stage TNBC patients. Furthermore, TNBC is a highly heterogeneous disease,

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

resulting in substantial differences in the tumorigenesis, treatment response, and disease progression among patients (Burstein et al., 2015; Jiang et al., 2019; Perou, 2011), which undoubtedly poses great challenges in prognostic prediction of the mTNBC and efficacy assessment for already limited treatment options. Unfortunately, reliable and tailored biomarkers to predict the prognosis and monitor the treatment response of patients with TNBC are yet to be established. It has been a long-standing clinical management model to predict the prognosis of patients with mTNBC and guide treatment decision-making through imaging examination and mutational features obtained by tumor biopsy. Imaging usually only provides the external characterization of the tumor, but can not reveal tumor internal molecular characteristics. Given the heterogeneity of TNBC, it is not possible to obtain an accurate and comprehensive picture of the mutational landscape using tissue biopsies unless repeated multiple biopsies(Diaz & Bardelli, 2014), and most patients are refractory to repetitive punctures. Compared with tissue biopsies, "liquid biopsies" collect and analyze tumor-derived substances, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes (e.g., from the blood, cerebrospinal fluid, and urine) of cancer patients in a minimally invasive fashion(Alix-Panabières & Pantel, 2016; Palmirotta et al., 2018; Poulet, Massias, & Taly, 2019). It can be used for early diagnosis of tumor patients, predicting tumor recurrence and metastasis, and evaluating the characteristics and clonal evolution of tumor genomes. ctDNA is a specific fraction of cell-free DNA (cfDNA), which is present in the plasma of apoptotic and necrotic tumor cells(Swarup & Rajeswari, 2007). Owing to special biological origin and the potential for multiple repeat sampling, ctDNA is independent of tumor spatial and temporal heterogeneity, convey more valuable information than a conventional tumor biopsy and enable the dynamic monitoring of tumor burden and treatment response(Campos-Carrillo et al., 2020; Chae & Oh, 2019; Dawson et al., 2013; Gerratana et al., 2021). The value of ctDNA in the accurate prediction of drug resistance and clinical outcomes has also been noted(Asante, Calapre, Ziman, Meniawy, & Gray, 2020; Murtaza et al., 2013). Several studies have demonstrated the prognostic and predictive value of ctDNA for

non-mTNBC during or after (neo)adjuvant therapy(Cavallone et al., 2020; H. Kim et al., 2021; Lin et al., 2021; Ortolan et al., 2021; Riva et al., 2017). Previously, researchers have also been relatively circumscribed concentrated on evaluating specific copy number variants (CNVs) or ctDNA-based single mutation or clonal evolution or the ctDNA level to predict the prognosis of mTNBC patients and the efficacy of specific treatment regimens(Barroso-Sousa et al., 2022; Chopra et al., 2020; Collier et al., 2021; Stover et al., 2018; Weber et al., 2021; Wongchenko et al., 2020). Even a study showed that the ctDNA level had no prognostic impact on survival of patients with mTNBC(Madic et al., 2015). A more comprehensive study of the mutational information and related markers embodied in ctDNA as well as a consensus on the predictive role of ctDNA in mTNBC are needed to apply ctDNA in clinical practice. Hence, in this study, we investigated the mutational characteristics of ctDNA and ctDNA-related markers in mTNBC using targeted, capture-based, next-generation sequencing (NGS), which offers rapid identification and high coverage from a small blood sample. We aimed to dynamically and more comprehensively evaluate the value of ctDNA in predicting the prognosis and monitoring the treatment response of patients with mTNBC.

Methods

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

Study design and sample collection

Between 2018 and 2021, patients with mTNBC who had progressed after \leq 2 lines of chemotherapy were prospectively enrolled. A 10 mL sample of peripheral blood was collected into an EDTA anticoagulant tube (STRECK Cell-Free DNA BCT®) from patients at different time points (i.e., before treatment, during treatment [treatment cycle 3, day 1], and at progression). Within 2 hours of collection, blood samples were centrifuged at $1,600 \times g$ for 10 min at 4 °C to obtain plasma, followed by secondary centrifugation at $16,000 \times g$ for 10 min at 4 °C to obtained peripheral blood cells. Plasma and peripheral blood cells were stored at -80 °C until the extraction of ctDNA and genomic DNA (gDNA). Paraffin-embedded primary or metastatic tumor tissues were collected before treatment and stored at room temperature for later use.

DNA extraction and targeted capture-based NGS

ctDNA was extracted from peripheral blood using the QIAamp Circulating Nucleic Acid Kit (Qiagen, Germany) while tumor DNA (tDNA) was extracted from the paraffin-embedded tumor tissues using the AllPrep DNA/RNA FFPE Kit (50) (Qiagen, Germany). Normal control gDNA was extracted from white blood cells using the DNeasy Kit (Qiagen, Germany) according to the manufacturer's instructions. The sequencing library was prepared from the ctDNA and tDNA samples using the KAPA DNA Library Preparation Kit (KAPA Biosystems, USA), while the gDNA sequencing library was constructed using the Illumina TruSeq DNA Library Preparation Kit (Illumina, USA). Library concentration was determined using real-time quantitative PCR and the KAPA Library Quantification Kit (KAPA Biosystems, USA). The library fragments were then size-selected using agarose gel electrophoresis. A targeted NGS panel of 457 genes (Supplementary Table 1), which are known to be frequently mutated in tumors, was designed to capture the target DNA fragments. Sequencing libraries were loaded onto a NovaSeq 6000 platform (Illumina, USA) with a 150-bp read length in paired-end mode.

Sequencing data analysis

Quality control of the raw sequencing data involved the use of FASTP to trim adapters and remove low-quality sequences(Chen, Zhou, Chen, & Gu, 2018). The clean reads were aligned against the Ensemble GRCh37/hg19 reference genome using BWA software(H. Li & Durbin, 2009). PCR duplications were processed using the gencore tool(Chen et al., 2019) and uniquely mapped reads were generated. The SAMtools suite was used to detect single-nucleotide variants (SNVs), insertions, and deletions(H. Li et al., 2009). CNVs were called using CONTRA(J. Li et al., 2012), with copy number > 3 as the threshold of copy number gain and < 1 as the threshold of copy number loss. The maximal tumor somatic variant allelic frequency (max-VAF) describes the highest mutated frequency of ctDNA detected in the cfDNA(Maron et al., 2019). The calculation of the ctDNA fraction (ctDNA%) was based on the autosomal somatic allele

fractions. The mutant allele fraction (MAF) and ctDNA% are related as follows: MAF = $(ctDNA \times 1)/([(1 - ctDNA) \times 2] + [ctDNA \times 1])$; thus, ctDNA = 2/(1/MAF + 1)(Vandekerkhove et al., 2017). The mutant-allele tumor heterogeneity (MATH) score was calculated as the percentage ratio of the width (median absolute deviation [MAD] scaled by a constant factor, so that the expected MAD of a sample from a normal distribution equals the standard deviation) to the center of the distribution of MAFs among the tumor-specific mutated loci; thus, MATH = $100 \times MAD/median(Mroz \& Rocco, 2013)$. Tumor mutational burden (TMB) was defined as the number of non-synonymous somatic mutations per megabase of genome examined(Chalmers et al., 2017).

Statistical analysis

The longest diameter (mm) of the tumor was measured by examining the radiological images. The response evaluation was carried out according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1)(Eisenhauer et al., 2009). The Kaplan–Meier method was used for the survival analyses; median comparison was performed using the log-rank test and hazard ratios (HRs) from the Cox proportional hazards model. The optimal cut-off values for ctDNA%, MATH score, and TMB were determined by the R package "survminer". Progression-free survival (PFS) was defined as the time interval from the initiation of the study to disease progression or death from any cause. Univariate Cox regression was carried out to analyze the mutations related to PFS; only genes mutated in > 5% of the patients were included in the analysis. The correlation between variables was analyzed using the Spearman correlation test and group comparisons were performed using the Wilcoxon rank-sum test. Statistical analysis and data visualization were conducted using R (version 4.0.1). The statistical significance was defined as bilateral P < 0.05.

Results

Study cohort and sample information

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198


199

200

201

A total of 126 patients with mTNBC were included in the study. Fifty-six patients were excluded, comprising 21 patients who had previously been treated with more than two lines of chemotherapy, 16 patients who were treated with combination therapy (e.g., chemotherapy with radiotherapy), 11 patients who were lost to follow-up, and 8 patients who failed to be evaluated for efficacy. Finally, 139 plasma samples (baseline samples from 70 patients and dynamic samples from 38/70 patients) from 70 patients and paired tumor tissues from 13 patients were collected and sequenced (Figure 1A, B). The patient baseline characteristics are shown in Table 1. The median age of all patients was 46 (26–75) years. Overall, 82.9% of patients were diagnosed with invasive ductal carcinoma and most of the patients developed visceral metastases at study entry. Table 2 shows that all patients received chemotherapy-based treatment with the most common chemotherapy drugs, such as gemcitabine, taxane, or platinum. Eleven patients were also treated with immunotherapy. The objective response rate was 38.6%, and 4, 23, 31, and 12 patients had complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD), respectively. The median PFS (mPFS) for all patients was 6.15 months (Supplementary Figure 1A). There was no significant difference in PFS among different treatment lines or regimens (Supplementary Figure 1B-H), although patients treated in the first line had a trend towards improved survival compared with those treated in the second and third lines.








Figure 1. Study design and sample collection. (**A**) Study flowchart. After excluding 82 patients, a total of 70 patients with mTNBC were included in the final analysis. Baseline blood samples were collected from all patients (n = 70) and paired tumor tissues were collected from 13 patients for NGS. (**B**) Blood-sample-derived ctDNA was dynamically monitored at baseline (yellow), during treatment (green), and at progression (orange) for 38 of the 70 patients. ctDNA, circulating tumor DNA; mTNBC, metastatic triple-negative breast cancer; NGS, next-generation sequencing.

Table 1. The baseline characteristics in study population.

Characteristics	All patients-no. (%)	Dynamic monitoring patients-no. (%			
	(n=70)	(n=38)			
Age (yrs), median (range)	46 (26-75)	47 (27-75)			
≤50	45 (64.3)	26 (68.4)			
>50	25 (35.7)	12 (31.6)			
Histopathologic diagnosis					
Invasive ductal carcinoma	58 (82.9)	29 (76.3)			
Other	10 (14.3)	7 (18.4)			
NA	2 (2.9)	2 (5.3)			
Pathological grade					
I-II	12 (17.1)	10 (26.3)			
III	39 (55.7)	20 (52.6)			
NA	19 (27.1)	8 (21.1)			
Disease stage at initial diagnosis					
I	7 (10.0)	5 (13.2)			
II	20 (28.6)	10 (26.3)			
III	33 (47.1)	20 (52.6)			
IV	7 (10.0)	3 (7.9)			
NA	3 (4.3)	0			
Disease-free interval (months)					
≤12 (including stage IV at initial	23 (32.9)	11 (28.9)			
diagnosis)					
>12	47 (67.1)	27 (71.1)			
Sites of metastasis					
Visceral	56 (80.0)	33 (86.8)			
Non-visceral	14 (20.0)	5 (13.2)			
Previous lines of chemotherapy					
during metastatic stage					
0	46 (65.7)	22 (57.9)			
1	19 (27.1)	11 (28.9)			
2	5 (7.1)	5 (13.2)			

Table 2. The treatment characteristics and responses of patients.

Treatment characteristics and responses	All patients-no. (%)	Dynamic monitoring patients-no. (%)			
	(n=70)	(n=38)			
Treatment regimens					
Contained gemcitabine + platinum	17 (24.3)	10 (26.3)			
Contained taxane + platinum	16 (22.9)	7 (18.4)			
Contained vinorelbine + platinum	4 (5.7)	1 (2.6)			
Contained taxane but no platinum	22 (31.4)	14 (36.8)			
Other	11 (15.7)	6 (15.8)			
Treatment modalities					
Immunotherapy + chemotherapy	11 (15.7)	6 (15.8)			
Chemotherapy	59 (84.3)	32 (84.2)			
Treatment responses					
CR	4 (5.7)	4 (10.5)			
PR	23 (32.9)	9 (23.7)			
SD	31 (44.3)	18 (47.4)			
PD	12 (17.1)	7 (18.4)			

Mutation characteristics of patients with mTNBC

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

Plasma samples were obtained from 70 patients with mTNBC before treatment and submitted for targeted NGS. In total, 203 mutated genes were identified using our panel of 457 genes, including 301 missense mutations, 45 frame-shift indels, 16 in-frame indels, 13 splice-site mutations, and 31 stop-gain mutations. The ten most frequently mutated genes were TP53 (69%), PIK3CA (24%), ARID1A (9%), KMT2C (9%), CIC (7%), KMT2D (7%), NOTCH4 (7%), PBRM1 (7%), PTEN (7%), and DNMT3A (6%). In addition, gene CNVs were detected in 351/457 genes, 296 of which showed copy number gain (CNG), 38 showed copy number loss, and 17 had both gain and loss mutations. The most prevalent genes with CNVs were HLA-C (50%), HLA-A (33%), HLA-B (33%), HLA-DRB1 (23%), SPPL3 (21%), BTG2 (19%), C8orf34 (16%), HLA-DQA1 (16%), HLA-E (16%), and LTBP1 (16%) (Figure 2A). We also used NGS to evaluate the discrepancy and consistency of genomic alterations in ctDNA samples and paired tumor tissues from 13 patients. The mutation frequency in plasma ctDNA was significantly lower than that in the tumor tissues (0.049% $\pm 0.113\%$ vs. $0.168 \pm 0.173\%$, P < 0.001) (Supplementary Figure 2). A total of 115 mutations in 85 genes were detected, which included 84 mutations in 63 genes from

plasma ctDNA and 81 mutations in 55 genes from tDNA. The number of ctDNA-specific and tDNA-specific mutated genes was 37 in both cases. Hence, the concordance rate between mutations in ctDNA and tDNA was 98.75% (**Figure 2B**).




Figure 2. Mutation characteristics of patients with mTNBC. (A) The landscape of ctDNA mutations in 70 patients with mTNBC prior to treatment initiation. The patients (n = 70) were divided into four groups (PD, SD, PR, and CR) according to the best treatment response (from left to right). The top half of the figure shows SNVs with a mutation frequency \geq 5%, and the bottom half shows CNVs with a mutation frequency \geq 10%; the different colored rectangles represent different types of variation. (B) Concordance between the genomic alterations in the blood-derived ctDNA and the tissue-derived tDNA. The mutated genes detected in at least two samples are shown here. The concordance rate = shared mutated genes/(all genes × the number of comparisons) × 100% = $(1 - [ctDNA-specific and tissue-specific mutated genes]/[all genes × the number of comparisons]) × 100% = <math>(1 - [37 + 37]/[457 \times 13]) \times 100\% = 98.75\%$. CNVs, copy number variants; CR, complete response; ctDNA, circulating tumor DNA; tDNA, tumor DNA;

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

mTNBC, metastatic triple-negative breast cancer; PD, progressive disease; PR, partial response; SD, stable disease; SNVs, single-nucleotide variants. A ctDNA+/- status correlates with the treatment response and survival of patients with mTNBC Univariate Cox regression analysis showed that 12 mutated genes, including HLA-B (HR, 95% confidence interval [CI]: 1.89, 1.08–3.32), BTG2 (HR, 95% CI: 2.23, 1.15– 4.31), MCL1 (HR, 95% CI: 2.31, 1.1–4.84), H3F3A (HR, 95% CI: 2.36, 1.08–5.16), MYC (HR, 95% CI: 3.45, 1.58–7.54), KMT2C (HR, 95% CI: 2.75, 1.14–6.63), KYAT3 (HR, 95% CI: 3.66, 1.48–9.04), ARID4B (HR, 95% CI: 4.04, 1.51–10.76), CD22 (HR, 95% CI: 3.66, 1.25–10.68), TGFB1 (HR, 95% CI: 3.94, 1.35–11.56), SGK1 (HR, 95% CI: 3.37, 1.15–9.82), and RSPO2 (HR, 95% CI: 4.19, 1.42–12.34), indicated a higher risk for recurrence or progression in patients with mTNBC (Figure 3A). Moreover, these 12 mutated genes were significantly associated with worse survival (Supplementary Figure 3). ctDNA was collected and evaluated at different time points and a plasma ctDNA sample with at least one of the 12 prognosis-relevant mutated genes was defined as ctDNA-positive (ctDNA+) (Figure 3B). The right half of Figure 3B shows that the mPFS in 70 patients with mTNBC was 6.15 months at a median follow-up of 19.13 months. As shown, ctDNA+ patients tended to have a shorter survival duration and less clinical benefit. At baseline, the ctDNA+ rates were 25%, 43%, 55%, and 33% in patients with CR, PR, SD, and PD, respectively. By comparing the ctDNA+/- status at all the time points, we found that the amount of ctDNA+ positively correlated with a worse treatment response. The proportion of ctDNA+ at different time points was 46% (at baseline), 29% (during treatment), and 44% (at progress), while that in the different treatment response groups was 45% (PD), 39% (SD), 22% (PR), and 0% (CR) (Figure **3C**). Prior to treatment, the tumor size of the ctDNA+ group was significantly larger than that of the ctDNA- group (52.56 \pm 34.65 mm vs. 40.18 \pm 35.49 mm, P < 0.001) (Figure 3D). We also found that patients who were ctDNA+ at baseline had a shorter PFS than those who were ctDNA- at baseline (5.16 months vs. 9.05 months, P = 0.001)

(**Figure 3E**). Multivariate Cox regression analysis, which included multiple clinical factors and ctDNA status, showed that ctDNA+ was independently associated with a shorter PFS (HR, 95% CI: 2.67, 1.2–5.96; P = 0.016) (**Table 3**).




Figure 3. Prognostic relevance of mutations in patients with mTNBC. (A) Twelve mutated genes, comprising HLA-B (CNG), BTG2 (CNG), MCL1 (CNG), H3F3A (CNG), MYC (CNG), KMT2C (SNV), KYAT3 (CNG), ARID4B (CNG), CD22 (CNG), TGFB1 (CNG), SGK1 (CNG), and RSPO2 (CNG) were identified as being associated with a higher risk of recurrence or progression in patients with mTNBC (all had HRs > 1 and a P < 0.05). (B) The left half of the figure summarizes the ctDNA status of all patients (n = 70) at different time points; among these, 38 patients also had their ctDNA status recorded during treatment and at progression. Solid dots represent ctDNA+ patients, while unfilled dots represent ctDNA- patients. The length of line segments in the right half of the figure denotes the PFS of patients, whereby the bars indicate the best response (PD, SD, PR, or CR) observed during treatment. (C) Comparison of ctDNA status (ctDNA+, red; ctDNA-, blue) among all the blood samples (n = 139) from patients

with different treatment responses (PD, SD, PR, or CR). (**D**) The tumor size of the ctDNA+ group at baseline was significantly greater than that of the ctDNA- group at baseline. (**E**) ctDNA+ at baseline was significantly associated with a shorter PFS. CNG, copy number gain; CR, complete response; ctDNA, circulating tumor DNA; ctDNA-, ctDNA negative; ctDNA+, ctDNA positive; HR, hazard ratio; mTNBC, metastatic triple-negative breast cancer; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease; SNV, single-nucleotide variant. A *P*-value < 0.05 was used as a measure of statistical significance.

Table 3. Multivariate cox regression analysis of multiple clinical factors and ctDNA status with PFS of patients.

Variable	HR (95 CI)	p value
Age ($\leq 50 \text{ vs.} > 50 \text{ years}$)	1.21 (0.47-3.1)	0.694
Histopathologic diagnosis (IDC vs. non-IDC)	0.64 (0.15-2.73)	0.55
Pathological grade (III vs. I-II)	1.23 (0.53-2.86)	0.629
DFI (\leq 12months vs. $>$ 12 nonths)	1.69 (0.6-4.71)	0.319
ctDNA status (ctDNA+ vs. ctDNA-)	2.67 (1.2-5.96)	0.016
T stage (T1 vs. T2 vs. T3)	0.75 (0.38-1.47)	0.397
N stage (N1 vs. N2 vs. N3)	0.79 (0.57-1.1)	0.161
CEA elevation (Yes vs. No)	1.75 (0.64-4.81)	0.278
CA125 elevation (Yes vs. No)	0.67 (0.24-1.88)	0.445
CA153 elevation (Yes vs. No)	1.86 (0.62-5.57)	0.268
Ki-67 (≥ 30% vs. < 30%)	0.78 (0.33-1.88)	0.582
Site of metastasis (visceral vs. non-visceral)	0.54 (0.18-1.61)	0.267
TMB (High vs. Low)	1.08 (0.38-3.09)	0.88

Baseline ctDNA-related markers are associated with mTNBC patient survival and treatment response

To further explore the value of ctDNA in predicting clinical outcomes in mTNBC, we examined the association between the pre-treatment ctDNA-related markers (i.e., TMB, MATH score, and ctDNA%) and PFS and the treatment response. Thus, we performed Kaplan–Meier analyses of TMB, MATH score, ctDNA%, and PFS in patients with mTNBC. Although not statistically significant, TMB-high (≥ 2.63) patients tended to have a shorter mPFS than the TMB-low (< 2.63) patients (5.87 months vs. 10.03 months, P = 0.057) (**Figure 4A**). Meanwhile, patients with a higher MATH score (≥ 6.316) had significantly shorter mPFS than patients with a lower MATH score (< 6.316) (5.67 months vs. 11.27 months, P = 0.007) (**Figure 4B**). Moreover, the higher ctDNA% (< 0.05) patient group had a significantly shorter mPFS than the lower ctDNA% (< 0.05)

group (5.45 months vs. 12.17 months, P < 0.001) (**Figure 4C**). Patients with mTNBC were categorized into the PD, SD, PR, and CR groups according to their response to treatment. Further comparative analysis of baseline ctDNA parameters in different treatment response groups revealed that TMB was progressively lower across the four groups, showing a decreasing trend from the PD group to the CR group. Compared with other treatment response groups, the PD group had a larger TMB (P = 0.032), greater MATH score (P = 0.003), and higher ctDNA% (P = 0.002) (**Figure 4D–F**).




Figure 4. The baseline-ctDNA-derived TMB, MATH score, and ctDNA% were associated with the clinical outcomes of patients with mTNBC. Higher TMB (≥ 2.63) (A), MATH score (≥ 6.316) (B), and ctDNA% (≥ 0.05) (C) were linked to a shorter PFS. The optimal cut-off values for TMB, MATH score, and ctDNA% were determined using the R package "survminer". Comparison of TMB (D), MATH score (E), and ctDNA% (F) in patients with different treatment responses (PD, SD, PR, or CR). CR, complete response; ctDNA, circulating tumor DNA; ctDNA%, ctDNA fraction; mTNBC, metastatic triple-negative breast cancer; PFS, progression-free survival; PD, progressive disease; PR, partial response; SD, stable disease; TMB, tumor mutational burden. A P-value < 0.05 was used as a measure of statistical significance.

Dynamic changes in ctDNA are associated with treatment response of patients with mTNBC

Figure 5A–D highlight the dynamic changes in ctDNA levels (i.e., mutations in 12 prognosis-relevant genes) and traditional tumor markers in each patient with PD (Patient 32), SD (Patient 31), PR (Patient 29), or CR (Patient 18). For instance in Patient 32, the MAF of *MYC* ctDNA increased significantly and was accompanied by increased

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

CA125 and CA153 levels and decreased CEA levels at the time of disease progression (Figure 5A). Figure 5B–D shows evidence of ctDNA mutations in Patient 31 (BTG2, ARID4B, CD22, H3F3A, HLA-B, MCL1, MYC, RSPO2), Patient 29 (BTG2, ARID4B, H3F3A, HLA-B, MCL1, MYC), and Patient 18 (BTG2, ARID4B, H3F3A, HLA-B, SGK1); their mutational rates dropped to the lowest level during the best response to treatment and rose again during progression. CA125 levels varied in line with treatment response and progression but no similar fluctuations were observed for CA153 and CEA. However, compared with the traditional tumor markers, dynamic changes in ctDNA mutations seemed to better mirror treatment-induced changes in tumor size. We therefore analyzed the correlation between the levels of serum tumor markers and tumor size on computed tomography (CT) scans during treatment (Figure 5E). We found that tumor size positively correlated with the MATH score (R = 0.24, P = 0.014) and ctDNA% (R = 0.3, P = 0.002), but not CEA, CA125, or CA153 levels. There were also strong positive correlations among the three ctDNA-related markers, TMB, MATH score, and ctDNA%. Moreover, the dynamic changes in ctDNA status may predict the prognosis of mTNBC. Kaplan-Meier analysis found that patients who remained ctDNA+ during dynamic monitoring had a shorter PFS than those who did not (3.90 months vs. 6.10 months, P = 0.135) (Figure 5F); however, this difference did not achieve statistical significance, most likely due to the limited sample size.




Figure 5. Dynamic ctDNA changes in patients with mTNBC. (A–D) Dynamic changes in tumor size were observed using computed tomography (CT) scans and the conventional tumor markers CEA, CA125, and CA153 (left side) or the VAF/copy number of 12 prognosis-relevant genes (right side) in four patients who each had a different best treatment response: PD (Patient 32), SD (Patient 31), PR (Patient 29), and CR (Patient 18). (E) The correlation between tumor size (measured using CT scans) and conventional tumor markers (CEA, CA125, CA153) or ctDNA parameters (TMB, MATH score, ctDNA%). Blue: positive correlation; red: negative correlation (the stronger the correlation, the darker the color). (F) Patients with a ctDNA+ status across all time points (All positive) tended to have a shorter PFS than those who were ctDNA— at least once during the process of dynamic monitoring (Other). CR, complete response; ctDNA, circulating tumor DNA; ctDNA—, ctDNA negative; ctDNA+, ctDNA positive; ctDNA%, ctDNA fraction; mTNBC, metastatic triple-negative breast cancer; PFS, progression-free survival; PD, progressive disease; PR, partial response; SD, stable disease; TMB, tumor mutational burden; VAF, variant allelic frequency. A *P*-value < 0.05 was used as a measure of statistical significance.

Discussion

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

Since the advent of precision medicine, liquid biopsies have become more widely utilized in the clinical management of cancer. In recent years, ctDNA has become the focus of extensive research as a predictive biomarker of tumor progression and/or treatment response. Several studies have explored the promising applications of ctDNA in breast cancer. For example, some researchers have investigated the longitudinal dynamics of ctDNA in the treatment monitoring of metastatic breast cancer, while others have studied the prognostic and predictive value of ctDNA during neoadjuvant chemotherapy for TNBC(Cavallone et al., 2020; Gerratana et al., 2021; Ortolan et al., 2021; Riva et al., 2017). However, the application of ctDNA in monitoring mTNBC is rare in clinical practice. In the current study, we performed targeted, capture-based NGS (with a 457-gene panel) on 139 plasma samples obtained by liquid biopsy from 70 patients with mTNBC. Thirteen paired tumor tissues were also analyzed to verify if ctDNA could be a feasible alternative to tumor-tissue-derived tDNA. This study demonstrated how a ctDNAbased platform could reliably reveal mutational profiles, stably predict the prognosis, and consistently monitor the treatment response of patients with mTNBC. This study also resolved the uncertainty of some current studies regarding the value of ctDNA and provided clear ctDNA-related predictive markers for mTNBC patients. By evaluating the mutational landscape of mTNBC in the Chinese population using ctDNA analysis, we showed that the most frequently mutated genes were TP53, PIK3CA, ARID1A, and KMT2C, and the most frequent CNV was detected in HLA-C, HLA-A, HLA-B, and HLA-DRB1 (Figure 2A). These genes play significant roles in the tumorigenesis, progression, invasion, and metastasis of breast cancer. In the homogeneous population, the most common mutations detected in tumor tissue were TP53, followed by PIK3CA, KMT2C, and PTEN; however, the top-ranking CNVs were found in different genes to those identified in a previous report: E2F3, IRS2, CCNE1, EGFR, NFIB, CCND1, and MYB(Jiang et al., 2019). This difference may be due to the fact that the plasma-derived ctDNA contains smaller fragments than those that are typically found in tissue-derived tDNA. Meanwhile, compared with the results of other ctDNA identification studies, the distribution of frequent variants in the TNBC cohort was overall consistent(Davis et al.,

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

2020; Rong et al., 2020; Wang et al., 2021). In the study by Chae et al., the concordance between all ctDNA- and tDNA-derived genes was also similar to that in our study (91.0%–94.2% vs. 98.75%)(Chae et al., 2017) (**Figure 2B**). The authors reported that the ctDNA-based assay had a high specificity, with a diagnostic accuracy of up to 80%. Although the mutation frequency of tDNA was higher than that of ctDNA in our study, the number of mutations detected in both types of DNA was similar. In addition, we detected 37 specific mutations in each of the ctDNA and tDNA groups, demonstrating the complementarity of blood-derived ctDNA and tissue-derived tDNA. Moreover, compared with tumor tissue analysis, ctDNA assays only require a small blood sample, can capture a variety of mutations (including SNVs and CNVs), and provide information on spatial tumor heterogeneity. Using NGS, we identified 12 prognosis-relevant mutated genes, which were associated with the shorter PFS of patients with mTNBC (Supplementary Figure 3). Most of the 12 genes have been linked to breast cancer by previous studies. For instance, the aberrant expression of KMT2C (low expression) and ARID4B (high expression) contribute to the poor prognosis of patients with ER-positive breast cancer(Sato & Akimoto, 2017; J. Zhang et al., 2021). However, previous studies have shown that the upregulated expression of BTG2 and CD22 were associated with improved survival, which is not in agreement with our current findings(Mascia et al., 2022; Y. J. Zhang et al., 2013); this may be due to the low number of patients included in this study. TGFB1, SGK1, RSPO2, and MCL1 are implicated in the invasion, migration, growth, autophagy, and progression of TNBC, while RSPO2 and MCL1 overexpression is associated with shorter survival rates in patients with TNBC(Coussy et al., 2017; S. Kim, Lee, Jeon, Nam, & Lee, 2015; Yang et al., 2014; Zhu et al., 2020). As a common driver of breast cancer, MYC amplification plays a role in emerging or acquired chemotherapy resistance during neoadjuvant treatment of TNBC and can also synergize with MCL1 amplification to maintain chemoresistance(Lee et al., 2017). HLA-B, a major histocompatibility complex (MHC) class I molecule, is involved in immunosurveillance against tumors and its expression is correlated with the invasiveness and prognosis of breast cancer(Concha, Esteban, Cabrera, Ruiz-Cabello,

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

& Garrido, 1991). To date, there have been no reports of an association between H3F3A or KYAT3 and breast cancer. Previously, H3F3A was identified as a driver gene in glioma, and its overexpression is linked to shorter survival rates and disease progression in lung cancer(Felker & Broniscer, 2020; Park et al., 2016). Thus, although the associations between of some of the 12 mutated genes identified in our study and cancer are known, their roles in the prognosis of mTNBC need to be further defined. We also explored the value of ctDNA status as a biomarker for predicting the prognosis and monitoring the treatment response of patients with mTNBC. We found that a ctDNA+ status was associated with a worse treatment response (Figure 3B, C). In addition, we showed that the ctDNA status at baseline could potentially discriminate between mTNBC patients with a high or low lesion load (Figure 3D), predict their prognosis (Figure 3E), and act as an independent prognostic factor (Table 3). This indicates that the ctDNA status, associated with the presence of the 12 prognosisrelevant mutated genes, may be a good guide to the prediction of clinical outcomes and the clinical management of TNBC. We further explored the optimal cut-off values for the ctDNA-based TMB, MATH score, and ctDNA% parameters at baseline using Kaplan–Meier analysis. A high MATH score (≥ 6.316) and high ctDNA% (≥ 0.05) were associated with a significantly shorter PFS (Figure 4B, C) and may therefore be related to the tumor burden of mTNBC. A study reported that most ctDNA fragments originate from metastases and not early-stage cancer, suggesting that ctDNA-based NGS may be more suitable for the analysis of metastatic tumors (Vandekerkhove et al., 2017). Unlike ctDNA%, the MATH score represents tumor heterogeneity. A previous study found that TNBC was associated with a higher MATH score(Ma, Jiang, Liu, Liu, & Shao, 2017). Moreover, patients with higher MATH ("Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology," 1996)scores tend to have more diverse tumor cell clones and may be more prone to drug resistance and progression(McDonald et al., 2019; Mroz & Rocco, 2013). Thus, the MATH score could also potentially be used as a biomarker for mTNBC prognosis. Breast cancer is a highly heterogeneous and dynamic disease; therefore, longitudinal

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

monitoring and management are necessary (Garcia-Murillas et al., 2015). The predictive value of ctDNA has prompted further exploration of its feasibility in the dynamic monitoring of the efficacy of neoadjuvant therapy for breast cancer, and in predicting the occurrence of distal metastasis and drug resistance(Cavallone et al., 2020; Darrigues et al., 2021; Wang et al., 2021). Here, we monitored ctDNA to track the dynamic changes in the 12 identified prognosis-related genes during the treatment of patients with mTNBC. The results showed that the elimination of these mutations or the reduction in the mutation rate of these genes was often associated with a better treatment response. Conversely, reappearance of these mutations at a later time point or an increase in their mutation rate signaled disease progression. Thus, we showed that the analysis of ctDNA was sensitive and accurately reflected the treatment response and disease status of patients with mTNBC in a timely manner. Conventional tumor markers have been widely used in clinical cancer management for some time("Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology," 1996). We found that, the serum CEA and CA153 levels contradicted the treatment response of Patient 31 at the mid-treatment time point (Figure 5B). The elevation of conventional tumor markers could indicate changes in the tumor and could be interpreted as an early warning of disease progression or pseudo-progression. However, this pseudo-progression or "tumor marker spike" is actually caused by extensive neoplastic cell necrosis induced by anti-tumor therapy. This phenomenon is observed in up to 30% of patients who respond to treatment(Seregni, Coli, & Mazzucca, 2004). NGS-mediated ctDNA detection identifies hundreds or thousands of mutations. Even if individual mutations were the result of a "ctDNA spike" (similar to a "tumor marker spike"), other mutations could be relied upon to accurately signal treatment efficacy. Moreover, we observed positive correlations between treatment response and MATH score and ctDNA%, but not the CEA, CA125, and CA153 levels (Figure 5E). Hence, compared with conventional tumor markers, ctDNA dynamics may better reflect treatment response and progression in mTNBC.

Several limitations exist in our study. First, this was a single-center study with a small

sample size. Second, the relatively short median follow-up duration was insufficient for capturing a clinically significant association between ctDNA mutations and overall survival. Third, several patients were lost to follow-up, which may have biased the results. Fourth, the potential influence of different treatment lines and regimens was not evaluated; nevertheless, no differences were found in survival based on these factors. Finally, compared with whole-exome sequencing or whole-genome sequencing, NGS with a panel of 457 selected genes, as used in our study, provided limited mutation data.

Conclusions

ctDNA profiling is a good alternative to tumor tissue sequencing and provides valuable insights into the mutational landscape of mTNBC. Furthermore, our study addressed the value of ctDNA in predicting the prognosis and monitoring the treatment response of patients with mTNBC. The results revealed that higher ctDNA%, MATH score, TMB, ctDNA+ status, and mutation rate were associated with a poor prognosis and a worse treatment response in mTNBC. Moreover, the longitudinal monitoring of genetic biomarkers in ctDNA was more sensitive and accurate for discerning treatment response or progression than traditional tumor markers such as CEA, CA125, and CA153. Taken together, these findings will contribute to a better understanding of ctDNA in mTNBC and may facilitate the development of a more accurate and non-invasive clinical strategy for managing patients with this condition. However, larger clinical trials are necessary to validate our results.

Additional information

Competing interests

The authors declare no potential conflicts of interest.

Funding

Funder	Grant No.	Author
National Natural Science Foundation of	81902713	Huihui Li
China		
Natural Science Foundation of Shandong	ZR2019LZL018	Jinming Yu
Province		

	st Disease Research Fund of Shandong YXH2020ZX066 Huihui Li incial Medical Association						
Start-up Fund of Shandong Cancer Hospital 2020-PYB10 Huihui Li							
Beijing Science and Technology Innovation KC2021-ZZ-0010-1 Huihui Li Fund							
524	Acknowledgments						
525	We sincerely thank the support of Yongsheng Wang, Pengfei Qiu, Binbin Cong, Peng						
526	Chen, Yanbing Liu, Chunjian Wang, Zhaopeng Zhang, Tong Zhao, Xiao Sun, Zhiyong						
527	Yu, Zhijun Huo, Xinzhao Wang, Shubin Song, Liang Zhang, Zhaoyun Liu, Fukai Wang,						
528	Chao Li, Xiang Song, Wenshu Zuo, Hui Fu, Meizhu Zheng, Ben Yang, Chao Han, Qian						
529	Shao, Xijun Liu, Jinzhi Wang, Wei Wang, Fengxiang Li, Yun Zhao, Linlin Wang,						
530	Bingjie Fan, Bing Zou, Zhenhua Gao, Xiangjiao Meng, Liyang Jiang, Zhengqiang Yang						
531	and Peng Xie. We also thank Liwen Bianji (Edanz) (www.liwenbianji.cn) for editing a						
532	draft of this manuscript.						
533	Ethics						
534	Human subjects: The study was approved by the Ethics Committee of Shandong Cancer						
535	Hospital and Institute (approval number: SDTHEC201806003) that collection of						
536	information, tumor tissues and blood samples within the ethical limitition of the patients,						
537	and conducted according to the Declaration of Helsinki. Written informed consent was						
538	obtained from all patients.						
539	Data Availability						
540	The raw sequence data generated during the current study have been deposited in the						
541	China National Genomics Data Center (https://ngdc.cncb.ac.cn/gsa-human/). The data						
542	under accession HRA002598 will be available on 27 June 2024 and are also available						
543	from the corresponding author upon reasonable request.						
544							
545	References						
546	Alix-Panabières, C., & Pantel, K. (2016). Clinical Applications of Circulating Tumor						
547	Cells and Circulating Tumor DNA as Liquid Biopsy. Cancer Discov, 6(5), 479-						
548	491. doi:10.1158/2159-8290.Cd-15-1483						
549	Asante, D. B., Calapre, L., Ziman, M., Meniawy, T. M., & Gray, E. S. (2020). Liquid						

biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for 550 prime time? Cancer Lett, 468, 59-71. doi:10.1016/j.canlet.2019.10.014 551 Barroso-Sousa, R., Forman, J., Collier, K., Weber, Z. T., Jammihal, T. R., Kao, K. Z., . . . 552 553 Tolaney, S. M. (2022). Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. JCO 554 Precis Oncol, 6, e2100413. doi:10.1200/po.21.00413 555 Burstein, M. D., Tsimelzon, A., Poage, G. M., Covington, K. R., Contreras, A., Fuqua, 556 S. A., . . . Brown, P. H. (2015). Comprehensive genomic analysis identifies 557 novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res, 558 21(7), 1688-1698. doi:10.1158/1078-0432.Ccr-14-0432 559 Campos-Carrillo, A., Weitzel, J. N., Sahoo, P., Rockne, R., Mokhnatkin, J. V., Murtaza, 560 M., ... Slavin, T. P. (2020). Circulating tumor DNA as an early cancer detection 561 562 tool. Pharmacol Ther, 207, 107458. doi:10.1016/j.pharmthera.2019.107458 Cavallone, L., Aguilar-Mahecha, A., Lafleur, J., Brousse, S., Aldamry, M., Roseshter, 563 T., . . . Basik, M. (2020). Prognostic and predictive value of circulating tumor 564 DNA during neoadjuvant chemotherapy for triple negative breast cancer. Sci 565 Rep, 10(1), 14704. doi:10.1038/s41598-020-71236-y 566 Chae, Y. K., Davis, A. A., Jain, S., Santa-Maria, C., Flaum, L., Beaubier, N., . . . 567 Cristofanilli, M. (2017). Concordance of Genomic Alterations by Next-568 Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in 569 570 Breast Cancer. Mol Cancer Ther, 16(7), 1412-1420. doi:10.1158/1535-7163.Mct-17-0061 571 Chae, Y. K., & Oh, M. S. (2019). Detection of Minimal Residual Disease Using ctDNA 572 in Lung Cancer: Current Evidence and Future Directions. J Thorac Oncol, 14(1), 573 16-24. doi:10.1016/j.jtho.2018.09.022 574 Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., . . . 575 Frampton, G. M. (2017). Analysis of 100,000 human cancer genomes reveals 576 the landscape of tumor mutational burden. Genome Med, 9(1), 34. 577 doi:10.1186/s13073-017-0424-2 578 Chen, S., Zhou, Y., Chen, Y., & Gu, J. (2018). fastp: an ultra-fast all-in-one FASTQ 579

Bioinformatics, 34(17), i884-i890. 580 preprocessor. doi:10.1093/bioinformatics/bty560 581 Chen, S., Zhou, Y., Chen, Y., Huang, T., Liao, W., Xu, Y., . . . Gu, J. (2019). Gencore: 582 583 an efficient tool to generate consensus reads for error suppressing and duplicate removing of NGS data. BMC Bioinformatics, 20(Suppl 23), 606. 584 doi:10.1186/s12859-019-3280-9 585 Chopra, N., Tovey, H., Pearson, A., Cutts, R., Toms, C., Proszek, P., . . . Turner, N. C. 586 (2020). Homologous recombination DNA repair deficiency and PARP 587 inhibition activity in primary triple negative breast cancer. Nat Commun, 11(1), 588 2662. doi:10.1038/s41467-020-16142-7 589 Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. 590 Adopted on May 17, 1996 by the American Society of Clinical Oncology. 591 592 (1996). J Clin Oncol, 14(10), 2843-2877. doi:10.1200/jco.1996.14.10.2843 Collier, K. A., Asad, S., Tallman, D., Jenison, J., Rajkovic, A., Mardis, E. R., . . . Stover, 593 D. G. (2021). Association of 17q22 Amplicon Via Cell-Free DNA With 594 Platinum Chemotherapy Response in Metastatic Triple-Negative Breast Cancer. 595 JCO Precis Oncol, 5. doi:10.1200/po.21.00104 596 Concha, A., Esteban, F., Cabrera, T., Ruiz-Cabello, F., & Garrido, F. (1991). Tumor 597 aggressiveness and MHC class I and II antigens in laryngeal and breast cancer. 598 Semin Cancer Biol, 2(1), 47-54. 599 600 Coussy, F., Lallemand, F., Vacher, S., Schnitzler, A., Chemlali, W., Caly, M., ... Bièche, I. (2017). Clinical value of R-spondins in triple-negative and metaplastic breast 601 cancers. Br J Cancer, 116(12), 1595-1603. doi:10.1038/bjc.2017.131 602 Darrigues, L., Pierga, J. Y., Bernard-Tessier, A., Bièche, I., Silveira, A. B., Michel, 603 M., . . . Bidard, F. C. (2021). Circulating tumor DNA as a dynamic biomarker 604 605 of response to palbociclib and fulvestrant in metastatic breast cancer patients. Breast Cancer Res, 23(1), 31. doi:10.1186/s13058-021-01411-0 606 Davis, A. A., Jacob, S., Gerratana, L., Shah, A. N., Wehbe, F., Katam, N., . . . 607 Cristofanilli, M. (2020). Landscape of circulating tumour DNA in metastatic 608 breast cancer. EBioMedicine, 58, 102914. doi:10.1016/j.ebiom.2020.102914 609

Dawson, S. J., Tsui, D. W., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S. F., . . . 610 Rosenfeld, N. (2013). Analysis of circulating tumor DNA to monitor metastatic 611 J breast N Engl Med, 368(13), 1199-1209. 612 cancer. 613 doi:10.1056/NEJMoa1213261 Diaz, L. A., Jr., & Bardelli, A. (2014). Liquid biopsies: genotyping circulating tumor 614 DNA. J Clin Oncol, 32(6), 579-586. doi:10.1200/jco.2012.45.2011 615 Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., . . . 616 Verweij, J. (2009). New response evaluation criteria in solid tumours: revised 617 guideline (version 1.1). Eur J Cancer, 45(2), 618 228-247. doi:10.1016/j.ejca.2008.10.026 619 Felker, J., & Broniscer, A. (2020). Improving long-term survival in diffuse intrinsic 620 Neurother, 20(7), 621 pontine glioma. Expert Rev 647-658. 622 doi:10.1080/14737175.2020.1775584 Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010). Triple-negative breast cancer. 623 N Engl J Med, 363(20), 1938-1948. doi:10.1056/NEJMra1001389 624 Garcia-Murillas, I., Schiavon, G., Weigelt, B., Ng, C., Hrebien, S., Cutts, R. J., . . . 625 Turner, N. C. (2015). Mutation tracking in circulating tumor DNA predicts 626 relapse in early breast cancer. Sci Transl Med, 7(302), 302ra133. 627 doi:10.1126/scitranslmed.aab0021 628 Gerratana, L., Davis, A. A., Zhang, Q., Basile, D., Rossi, G., Strickland, K., . . . 629 630 Cristofanilli, M. (2021). Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer. 631 JCO Precis Oncol, 5, 943-952. doi:10.1200/po.20.00345 632 Jiang, Y. Z., Ma, D., Suo, C., Shi, J., Xue, M., Hu, X., ... Shao, Z. M. (2019). Genomic 633 and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes 634 and Treatment Strategies. Cancer Cell, 35(3), 428-440.e425. 635 doi:10.1016/j.ccell.2019.02.001 636 Kim, H., Kim, Y. J., Park, D., Park, W. Y., Choi, D. H., Park, W., . . . Kim, N. (2021). 637 Dynamics of circulating tumor DNA during postoperative radiotherapy in 638 patients with residual triple-negative breast cancer following neoadjuvant 639

- chemotherapy: a prospective observational study. Breast Cancer Res Treat,
- 189(1), 167-175. doi:10.1007/s10549-021-06296-3
- 642 Kim, S., Lee, J., Jeon, M., Nam, S. J., & Lee, J. E. (2015). Elevated TGF-β1 and -β2
- expression accelerates the epithelial to mesenchymal transition in triple-
- negative breast cancer cells. Cytokine, 75(1), 151-158.
- doi:10.1016/j.cyto.2015.05.020
- Lee, K. M., Giltnane, J. M., Balko, J. M., Schwarz, L. J., Guerrero-Zotano, A. L.,
- Hutchinson, K. E., . . . Arteaga, C. L. (2017). MYC and MCL1 Cooperatively
- Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of
- Mitochondrial Oxidative Phosphorylation. Cell Metab, 26(4), 633-647.e637.
- doi:10.1016/j.cmet.2017.09.009
- 651 Li, H., & Durbin, R. (2009). Fast and accurate short read alignment with Burrows-
- Wheeler transform. Bioinformatics, 25(14), 1754-1760.
- doi:10.1093/bioinformatics/btp324
- Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., . . . Durbin, R.
- 655 (2009). The Sequence Alignment/Map format and SAMtools. Bioinformatics,
- 656 25(16), 2078-2079. doi:10.1093/bioinformatics/btp352
- 657 Li, J., Lupat, R., Amarasinghe, K. C., Thompson, E. R., Doyle, M. A., Ryland, G. L., . . .
- Gorringe, K. L. (2012). CONTRA: copy number analysis for targeted
- resequencing. Bioinformatics, 28(10), 1307-1313.
- doi:10.1093/bioinformatics/bts146
- 661 Li, X., Yang, J., Peng, L., Sahin, A. A., Huo, L., Ward, K. C., . . . Meisel, J. L. (2017).
- Triple-negative breast cancer has worse overall survival and cause-specific
- survival than non-triple-negative breast cancer. Breast Cancer Res Treat, 161(2),
- 664 279-287. doi:10.1007/s10549-016-4059-6
- 665 Lin, P. H., Wang, M. Y., Lo, C., Tsai, L. W., Yen, T. C., Huang, T. Y., . . . Huang, C. S.
- 666 (2021). Circulating Tumor DNA as a Predictive Marker of Recurrence for
- Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy.
- 668 Front Oncol, 11, 736769. doi:10.3389/fonc.2021.736769
- 669 Ma, D., Jiang, Y. Z., Liu, X. Y., Liu, Y. R., & Shao, Z. M. (2017). Clinical and molecular

relevance of mutant-allele tumor heterogeneity in breast cancer. Breast Cancer 670 Res Treat, 162(1), 39-48. doi:10.1007/s10549-017-4113-z 671 Madic, J., Kiialainen, A., Bidard, F. C., Birzele, F., Ramey, G., Leroy, Q., ... Lebofsky, 672 673 R. (2015). Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. Int J Cancer, 136(9), 2158-2165. 674 doi:10.1002/ijc.29265 675 Malorni, L., Shetty, P. B., De Angelis, C., Hilsenbeck, S., Rimawi, M. F., Elledge, R., . . . 676 Arpino, G. (2012). Clinical and biologic features of triple-negative breast 677 cancers in a large cohort of patients with long-term follow-up. Breast Cancer 678 Res Treat, 136(3), 795-804. doi:10.1007/s10549-012-2315-y 679 Maron, S. B., Chase, L. M., Lomnicki, S., Kochanny, S., Moore, K. L., Joshi, S. S., . . . 680 Catenacci, D. V. T. (2019). Circulating Tumor DNA Sequencing Analysis of 681 682 Gastroesophageal Adenocarcinoma. Clin Cancer Res, 25(23), 7098-7112. doi:10.1158/1078-0432.Ccr-19-1704 683 Mascia, F., Mazo, I., Alterovitz, W. L., Karagiannis, K., Wu, W. W., Shen, R. F., . . . 684 Rao, V. A. (2022). In search of autophagy biomarkers in breast cancer: Receptor 685 status and drug agnostic transcriptional changes during autophagy flux in cell 686 lines. PLoS One, 17(1), e0262134. doi:10.1371/journal.pone.0262134 687 McDonald, K. A., Kawaguchi, T., Qi, Q., Peng, X., Asaoka, M., Young, J., . . . Takabe, 688 K. (2019). Tumor Heterogeneity Correlates with Less Immune Response and 689 690 Worse Survival in Breast Cancer Patients. Ann Surg Oncol, 26(7), 2191-2199. doi:10.1245/s10434-019-07338-3 691 Mroz, E. A., & Rocco, J. W. (2013). MATH, a novel measure of intratumor genetic 692 heterogeneity, is high in poor-outcome classes of head and neck squamous cell 693 49(3), carcinoma. Oral Oncol, 211-215. 694 doi:10.1016/j.oraloncology.2012.09.007 695 Murtaza, M., Dawson, S. J., Tsui, D. W., Gale, D., Forshew, T., Piskorz, A. M., . . . 696 Rosenfeld, N. (2013). Non-invasive analysis of acquired resistance to cancer 697 therapy by sequencing of plasma DNA. Nature, 497(7447), 108-112. 698 doi:10.1038/nature12065 699


- 700 Ortolan, E., Appierto, V., Silvestri, M., Miceli, R., Veneroni, S., Folli, S., ... Di Cosimo,
- S. (2021). Blood-based genomics of triple-negative breast cancer progression in
- patients treated with neoadjuvant chemotherapy. ESMO Open, 6(2), 100086.
- 703 doi:10.1016/j.esmoop.2021.100086
- Palmirotta, R., Lovero, D., Cafforio, P., Felici, C., Mannavola, F., Pellè, E., ... Silvestris,
- F. (2018). Liquid biopsy of cancer: a multimodal diagnostic tool in clinical
- 706 oncology. Ther Adv Med Oncol, 10, 1758835918794630.
- 707 doi:10.1177/1758835918794630
- 708 Park, S. M., Choi, E. Y., Bae, M., Kim, S., Park, J. B., Yoo, H., . . . Kim, I. H. (2016).
- Histone variant H3F3A promotes lung cancer cell migration through intronic
- regulation. Nat Commun, 7, 12914. doi:10.1038/ncomms12914
- 711 Perou, C. M. (2011). Molecular stratification of triple-negative breast cancers.
- 712 Oncologist, 16 Suppl 1, 61-70. doi:10.1634/theoncologist.2011-S1-61
- Poulet, G., Massias, J., & Taly, V. (2019). Liquid Biopsy: General Concepts. Acta Cytol,
- 714 63(6), 449-455. doi:10.1159/000499337
- Riva, F., Bidard, F. C., Houy, A., Saliou, A., Madic, J., Rampanou, A., . . . Pierga, J. Y.
- 716 (2017). Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant
- 717 Chemotherapy in Triple-Negative Breast Cancer. Clin Chem, 63(3), 691-699.
- 718 doi:10.1373/clinchem.2016.262337
- 719 Rong, G., Yi, Z., Ma, F., Guan, Y., Xu, Y., Li, L., & Xu, B. (2020). Mutational
- 720 characteristics determined using circulating tumor DNA analysis in triple-
- negative breast cancer patients with distant metastasis. Cancer Commun (Lond),
- 722 40(12), 738-742. doi:10.1002/cac2.12102
- 723 Sato, K., & Akimoto, K. (2017). Expression Levels of KMT2C and SLC20A1
- 724 Identified by Information-theoretical Analysis Are Powerful Prognostic
- Biomarkers in Estrogen Receptor-positive Breast Cancer. Clin Breast Cancer,
- 726 17(3), e135-e142. doi:10.1016/j.clbc.2016.11.005
- 727 Seregni, E., Coli, A., & Mazzucca, N. (2004). Circulating tumour markers in breast
- 728 cancer. Eur J Nucl Med Mol Imaging, 31 Suppl 1, S15-22. doi:10.1007/s00259-
- 729 004-1523-z

Stover, D. G., Parsons, H. A., Ha, G., Freeman, S. S., Barry, W. T., Guo, H., . . . 730 Adalsteinsson, V. A. (2018). Association of Cell-Free DNA Tumor Fraction and 731 Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative 732 733 Breast Cancer. J Clin Oncol, 36(6), 543-553. doi:10.1200/jco.2017.76.0033 Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, 734 F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence 735 and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 736 71(3), 209-249. doi:10.3322/caac.21660 737 Swarup, V., & Rajeswari, M. R. (2007). Circulating (cell-free) nucleic acids--a 738 promising, non-invasive tool for early detection of several human diseases. 739 FEBS Lett, 581(5), 795-799. doi:10.1016/j.febslet.2007.01.051 740 Vandekerkhove, G., Todenhöfer, T., Annala, M., Struss, W. J., Wong, A., Beja, K., . . . 741 742 Wyatt, A. W. (2017). Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. Clin Cancer Res, 23(21), 6487-743 6497. doi:10.1158/1078-0432.Ccr-17-1140 744 Wang, Y., Lin, L., Li, L., Wen, J., Chi, Y., Hao, R., . . . Wang, O. (2021). Genetic 745 landscape of breast cancer and mutation tracking with circulating tumor DNA 746 Chinese (Albany 13(8), 11860-11876. 747 in women. Aging NY), doi:10.18632/aging.202888 748 Weber, Z. T., Collier, K. A., Tallman, D., Forman, J., Shukla, S., Asad, S., . . . Stover, 749 750 D. G. (2021). Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer. Genome Med, 13(1), 89. 751 doi:10.1186/s13073-021-00895-x 752 Wongchenko, M. J., Kim, S. B., Saura, C., Oliveira, M., Lipson, D., Kennedy, M., . . . 753 Dent, R. (2020). Circulating Tumor DNA and Biomarker Analyses From the 754 LOTUS Randomized Trial of First-Line Ipatasertib and Paclitaxel for 755 Metastatic Triple-Negative Breast Cancer. JCO Precis Oncol, 4, 1012-1024. 756 doi:10.1200/po.19.00396 757 Yang, L., Perez, A. A., Fujie, S., Warden, C., Li, J., Wang, Y., . . . Yen, Y. (2014). Wnt 758 modulates MCL1 to control cell survival in triple negative breast cancer. BMC 759

Cancer, 14, 124. doi:10.1186/1471-2407-14-124 Zhang, J., Hou, S., You, Z., Li, G., Xu, S., Li, X., ... Pang, D. (2021). Expression and prognostic values of ARID family members in breast cancer. Aging (Albany NY), 13(4), 5621-5637. doi:10.18632/aging.202489 Zhang, Y. J., Wei, L., Liu, M., Li, J., Zheng, Y. Q., Gao, Y., & Li, X. R. (2013). BTG2 inhibits the proliferation, invasion, and apoptosis of MDA-MB-231 triple-negative breast cancer cells. Tumour Biol, 34(3),1605-1613. doi:10.1007/s13277-013-0691-5 Zhu, R., Yang, G., Cao, Z., Shen, K., Zheng, L., Xiao, J., . . . Zhang, T. (2020). The prospect of serum and glucocorticoid-inducible kinase 1 (SGK1) in cancer therapy: a rising star. Ther Adv Med Oncol, 12, 1758835920940946. doi:10.1177/1758835920940946


Supplement table 1. The list of 457 genes detected in this study.

	11			or is a gene						
ABL1	BRCA1	CDKN2C	ERBB3	GABRA6	IRF4	MAPK8IP1	NOTCH4	POLE	RPA3	TEK
ACVR1B	BRCA2	CEBPA	ERBB4	GAGE1	IRS2	MCL1	NPM1	POLQ	RPL22	TENT5C
ACVR2A	BRD4	CHEK1	ERCC2	GALNT12	ITK	MDM2	NRAS	PPARG	RPL5	TET1
AJUBA	BRIP1	CHEK2	ERCC3	GATA1	JAK1	MDM4	NRG1	PPM1D	RPTOR	TET2
AKT1	BTG1	CIC	ERCC4	GATA2	JAK2	MECOM	NSD1	PPP2R1A	RUNX1	TGFB1
AKT2	BTG2	CREBBP	ERCC5	GATA3	JAK3	MED12	NSD2	PPP2R2A	SDHA	TGFBR2
AKT3	BTK	CRIPAK	ERG	GATA4	JUN	MEF2B	NSD3	PRDM1	SDHB	TIPARP
ALK	BTLA	CRKL	ERRFI1	GATA6	KDM5A	MEN1	NT5C2	PRF1	SDHC	TLR4
ALOX12B	EMSY	CSF1R	ESR1	GID4 (C17orf39)	KDM5C	MERTK	NT5E	PRKAR1A	SDHD	TNF
AMER1	CALR	CSF3R	ETV1	GNA11	KDM6A	MET	NTRK1	PRKCI	SETBP1	TNFAIP3
APC	CARD11	CTAG2	EZH2	GNA13	KDR	MGMT	NTRK2	PRX	SETD2	TNFRSF14
AR	CASP8	CTCF	FANCA	GNAQ	KEAP1	MITF	NTRK3	PTCH1	SF3B1	TNFRSF18
ARAF	CBFB	CTLA4	FANCC	GNAS	KEL	MKNK1	P2RY8	PTEN	SGK1	TNFRSF4
ARFRP1	CBL	CTNNA1	FANCG	GREM1	KIT	MLH1	PALB2	PTK6	SH2D1A	TNFSF11
ARHGAP35	CCND1	CTNNB1	FANCL	GRM3	KITLG	MLH3	PRKN	PTPN11	SIK1	TNFSF14
ARHGEF12	CCND2	CUL3	FANCM	GSK3B	KLHL6	MPL	PARP1	PTPRD	SIN3A	TNFSF18
ARID1A	CCND3	CUL4A	FAS	H3F3A	KMT2A	MRE11	PARP2	PTPRK	SLAMF7	TNFSF4
ARID2	CCNE1	CXCR4	FBXW7	H3F3C	KMT2B	MSH2	PARP3	PTPRO	SMAD2	TOP1
ARID5B	CD160	CYP17A1	FGF10	HAVCR2	KMT2C	MSH3	PAX5	PTPRT	SMAD4	TP53
ASXL1	CD22	DAXX	FGF12	HDAC1	KMT2D	MSH6	PBRM1	QKI	SMARCA4	TSC1
ATM	CD244	DDR1	FGF14	HDAC2	KRAS	MST1R	PCBP1	RAC1	SMARCB1	TSC2
ATR	CD274	DDR2	FGF19	HDAC3	LAG3	MTAP	PCNA	RAD21	SMC1A	TSHR
ATRX	CD276	DICER1	FGF23	HDAC6	LCK	MTOR	PDCD1	RAD50	SMC3	TSHZ2
AURKA	CD28	DIS3	FGF3	HGF	LEF1	MUTYH	PDCD1LG2	RAD51	SMO	TSHZ3
AURKB	CD38	DNMT3A	FGF4	HIST1H1C	LIFR	MYC	PDGFRA	RAD51B	SNCAIP	TYRO3
AXIN1	CD48	DOT1L	FGF6	HIST1H2BD	LIMK1	MYCL	PDGFRB	RAD51C	SOCS1	U2AF1
AXIN2	CD69	EED	FGFR1	HNF1A	LRRK2	MYCN	PDK1	RAD51D	SOX17	USP9X
AXL	CD70	EGFR	FGFR2	HRAS	LTK	MYD88	PHF6	RAD52	SOX2	VEGFA
B2M	CD79A	EGR3	FGFR3	HSD3B1	LYN	NAV3	PHOX2B	RAD54L	SOX9	VEGFB
B4GALT3	CD79B	EIF4A2	FGFR4	ICOS	MAF	NBN	PIGF	RAF1	SPATA2	VEZF1
BAGE	CD80	ELF3	FH	ICOSLG	MAGEA1	NCOA4	PIK3C2B	RARA	SPEN	VHL
BAP1	CD86	EOMES	FLCN	ID3	MAGEA12	NCOR1	PIK3C2G	RB1	SPOP	VTCN1
BARD1	CDC73	EP300	FLT1	IDH1	MAGEA3	NEK11	PIK3CA	RBM10	SRC	WT1
BCL2	CDH1	EPCAM	FLT3	IDH2	MAGEA4	NF1	PIK3CB	RECQL	STAG2	XPO1
BCL2L1	CDK12	EPHA1	FLT4	IGF1R	MAGEC2	NF2	PIK3CD	RECQL4	STAT3	XRCC2
BCL2L2	CDK4	EPHA2	FOXA1	IGF2	MAP2K1	NFE2L2	PIK3CG	REL	STK11	ZNF217
BCL6	CDK6	ЕРНА3	FOXA2	IKBKE	MAP2K2	NFE2L3	PIK3R1	RET	SUFU	ZNF703
BCOR	CDK8	EPHB1	FOXL2	IKZF1	MAP2K4	NFKBIA	PIK3R2	RICTOR	SYK	
BCORL1	CDKN1A	ЕРНВ4	FOXO3	IL7R	MAP3K1	NKX2-1	PIM1	RNF43	TAF1	
BLM	CDKN1B	ЕРНВ6	FOXP1	INPP4B	MAP3K13	NOTCH1	PMS1	ROS1	TAS2R38	
BMPR1A	CDKN2A	EPPK1	FRK	INSR	MAPK1	NOTCH2	PMS2	RPA1	TBL1XR1	
BRAF	CDKN2B	ERBB2	FUBP1	IRF2	MAPK11	NOTCH3	POLD1	RPA2	TBX3	
		L	<u> </u>						l	




Supplementary Figure 1. (A) Kaplan–Meier analysis of PFS in all patients with mTNBC. (B) Kaplan–Meier analysis of PFS in patients with different lines of treatment. (C–H) Kaplan–Meier analysis of PFS in patients treated with distinct treatment regimens. GP, gemcitabine- and platinum-based treatment; IC, immunotherapy plus chemotherapy; mTNBC, metastatic triple-negative breast cancer; P, platinum-based treatment; PFS, progression-free survival; T, taxane-based treatment; TP, taxane- and platinum-based treatment. A P-value < 0.05 was used as a measure of statistical significance.

Supplementary Figure 2



Supplementary Figure 2. Comparison of mutation frequency between ctDNA and tissue. The mutation frequency in ctDNA was significantly lower than that in tissues (P < 0.001). ctDNA, circulating tumor DNA. A P-value < 0.05 was used as a measure of statistical significance.



Supplementary Figure 3. Kaplan–Meier analysis of the PFS of 12 prognosis-relevant mutated genes in patients with mTNBC. Patients with mutated HLA-B (A), MYC (B), CD22 (C), BTG2 (D), KMT2C (E), TGFB1 (F), MCL1 (G), KYAT3 (H), SGK1 (I), H3F3A (J), ARID4B (K), or RSPO2 (L) had a significantly shorter PFS. Gain = copy number gain; mTNBC, metastatic triple-negative breast cancer patients; Mut, mutated; PFS, progression-free survival. WT, wild type. A P-value < 0.05 was used as a measure of statistical significance.